Wolfe Research upgraded Intellia Therapeutics (NTLA) to Outperform from Peer Perform with a $21 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- NTLA Lawsuit Alert! Class Action Lawsuit Against Intellia Therapeutics Inc.
- Intellia Therapeutics announces first patient dosed in MAGNITUDE-2 trial
- Biotech stocks slide as Marks resignation seen being negative for sector
- BMO says Peter Marks resignation ‘significant negative’ for biotech
- Intellia Therapeutics announces FDA RMAT designation to nex-z